Micvotabart pelidotin - Pyxis Oncology
Alternative Names: anti-EDB; MICVO; PYX-201Latest Information Update: 06 May 2025
At a glance
- Originator Pfizer
- Developer Merck & Co; Pyxis Oncology
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a Preclinical trial in Cancer released by Pyxis Oncology
- 03 Mar 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in USA (IV) (NCT06795412)
- 26 Feb 2025 PYX 201 receives Fast Track designation for Solid tumours [IV,Infusion] (Late-stage disease, Second-line therapy or greater) in USA